Free Trial

Joseph Thome Analyst Performance

Analyst at Oppenheimer

Joseph Thome is a stock analyst at Oppenheimer focused in the medical sector, covering 8 publicly traded companies. Over the past year, Joseph Thome has issued 16 stock ratings, including strong buy, buy, and hold recommendations. While full access to Joseph Thome's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Joseph Thome's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
18 Last 5 Years
Buy Recommendations
83.33% 15 Buy Ratings
Companies Covered
8 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy5.6%1 ratings
Buy77.8%14 ratings
Hold16.7%3 ratings
Sell0.0%0 ratings

Out of 18 total stock ratings issued by Joseph Thome at Oppenheimer, the majority (77.8%) have been Buy recommendations, followed by 16.7% Hold and 5.6% Strong Buy.

Best & Worst Calls

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
8 companies

Joseph Thome, an analyst at Oppenheimer, currently covers 8 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
7 companies
87.5%
Manufacturing
1 company
12.5%

Joseph Thome of Oppenheimer specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
5 companies
62.5%
MED - DRUGS
2 companies
25.0%
Miscellaneous
1 company
12.5%

Joseph Thome's Ratings History at Oppenheimer

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
6/9/2026Initiated Coverage$6.77$20.00Outperform
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
5/21/2026Reiterated Rating$563.41Buy
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
5/8/2026Upgrade$64.49$90.00Buy
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
5/7/2026Boost Price Target$101.07$145.00Buy
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
5/6/2026Boost Price Target$225.73$275.00Buy
Maplight Therapeutics, Inc. stock logo
MPLT
Maplight Therapeutics
4/7/2026Initiated Coverage$22.61Buy
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
3/30/2026Boost Price Target$592.66$660.00Buy
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
3/27/2026Boost Price Target$89.56$125.00Buy
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
2/26/2026Boost Price Target$93.02$117.00Buy
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
2/25/2026Boost Price Target$535.10$575.00Buy
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
1/29/2026Reiterated Rating$77.23Hold
Ardelyx, Inc. stock logo
ARDX
Ardelyx
1/29/2026Reiterated Rating$7.78Buy
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
11/5/2025Boost Price Target$71.00$63.00Hold
Ardelyx, Inc. stock logo
ARDX
Ardelyx
10/31/2025Boost Price Target$6.06$10.00Buy
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
9/25/2025Upgrade$73.57Strong-Buy
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
9/24/2025Initiated Coverage$73.62$95.00Buy
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
5/13/2025Initiated Coverage$33.88Buy